Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2007-08-24
2009-10-27
Lewis, Patrick T (Department: 1623)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C514S043000, C514S049000, C514S051000, C536S028100, C536S028400
Reexamination Certificate
active
07608602
ABSTRACT:
The present invention provides gemcitabine prodrugs, methods of making gemcitabine prodrugs, pharmaceutical compositions of gemcitabine prodrugs and methods of using gemcitabine prodrugs and pharmaceutical compositions of using gemcitabine prodrugs to treat or prevent diseases or disorders such as cancer or viral infections.
REFERENCES:
patent: 3845770 (1974-11-01), Theeuwes et al.
patent: 3916899 (1975-11-01), Theeuwes et al.
patent: 5401838 (1995-03-01), Boniouklian et al.
patent: 5426183 (1995-06-01), Kjell
patent: 5521294 (1996-05-01), Wildfeuer
patent: 5594124 (1997-01-01), Chou
patent: 5606048 (1997-02-01), Chou et al.
patent: 5698155 (1997-12-01), Grosswald et al.
patent: 6303569 (2001-10-01), Greenwald et al.
patent: 2003/0158089 (2003-08-01), Gallop et al.
patent: 0272891 (1988-06-01), None
patent: 0272891 (1988-06-01), None
patent: 329348 (1989-08-01), None
patent: 329348 (1989-08-01), None
patent: 0376518 (1990-07-01), None
patent: 576230 (1993-12-01), None
patent: 577303 (1994-01-01), None
patent: 712860 (1996-05-01), None
patent: 712860 (1996-05-01), None
patent: WO 91/15498 (1991-10-01), None
patent: WO 91/15498 (1991-10-01), None
patent: WO 98/00173 (1998-01-01), None
patent: WO 98/00173 (1998-01-01), None
patent: WO 98/32762 (1998-07-01), None
patent: WO 99/33483 (1999-07-01), None
patent: WO 01/20331 (2001-03-01), None
patent: WO 01/21135 (2001-03-01), None
patent: WO 01/21135 (2001-03-01), None
patent: WO 03/043631 (2003-05-01), None
Adibi, “The oligopeptide transporter (Pept-1) in Human Intestine: Biology and Function,”Gastroenterology1997, 113, 332-340.
Akrivakis et al., “Prolonged infusion of Gemcitabine in stage IV breast cancer: a phase I study,”Anti-Cancer Drugs1999, 10, 525-531.
Alderman, “A Review of cellulose Ethers in Hydrophilic Matrices dor Oral controlled-Release Dosage Forms,”Int. J. Pharm. Tech. &Prod. Mfr. 1984, 5(3) 1-9.
Alexander et al., “Synthesis and cytotoxic activity of two novel 1-dodecylthio-2-decyloxypropyl-3-phosphatidic acid conjugates with gemcitabine and cytosine arabinoside,”J. Med. Chem. 2003, 46, 4205-4208.
Baker et al., “2′-Deoxy-2′-methylenecytidine and 2′-deoxy-2′,2′-difluorocytidine 5′-diphosphates: potent mechanism-based inhibitors of ribonucleotide reductase,”J. Med. Chem. 1991, 34. 1879-1884.
Balimane et al., “Involvement of multiple transporters in the oral absorption of nucleoside analogues,”Adv Drug Deliv Rev. 1999 Oct18;39(1-3):183-209.
Bamba et al., “Release Mechanisms in Gelforming Sustained Release Preparations,”Int. J. Pharm. 1979, 2, 307.
Chatterjee et al., “Molecular mechanism of the intestinal biotin transport process,”Am. J. Physiol. 1999, 277, 605-613.
Chou et al., “Stereospecific Synthetic of 2-Doexy-2,2-difluororibonolactone and Its Use in Preparation of 2′Deoxy-2′,2′-difluro-β-D-Ribofuranosyl Pyrimidine Necleosides: The Key Role of Selective Crystalization,”Synthesis, 1992, 565-570.
Collins et al., “Scanning Mutagenesis of the Putative Transmembrane Segments of Kir2.1, an Inward Rectifier Potassium Channel,”Proceedings National Academy of Science, 1997; 94: 5456-5460.
Crawford et al., “Cloning of the Human Equilibrative, Nitrobenzylmercaptopurine Riboside (NBMPR)-insensitive Nucleoside Transportereiby Functional Expression in a Transport-deficient Cell Line,”J. Biol. Chem. 1998, 273, 5288-5293.
Di Stefano et al., “Inhibition of [3H]thymidine incorporation into DNA of rat regenerating liver 2′,2-40 -difluorodeoxycytidine coupled to lactosaminated poly-L-lysine,”Biochem. Pharmacol. 1999, 57(7), 793-799.
During et al., “Controlled release of dopamine from a polymeric brain implant: in vivo characterization,” 1989,Ann. Neurol. 25:351.
Fang et al., “Functional characterization of a recombinant sodium-dependent nucleoside transporter with selectivity for pyrimidine nucleosides (cNT1rat) by transient expression in cultured mammalian cells,”Biochem. J. 1996, 317, 457-465.
Gandhi et al., “Prolonged Infusion of Gemcitabine: Clinical and Pharmacodynamic Studies During a Phase I Trial in Relapsed Acute Myelogenous Leukemia,”J. Clin. Oncol. 2002, 20, 665-673.
Goodson, in “Medical Applications of Controlled Release,”supra, vol. 2, pp. 115-138 (1984).
Green, “Gemcitabine safety overview,”Semin Oncol. 1996, 23 (5 Suppl 10), 32-35.
Griffiths et al., “Cloning of a human nucleoside transporter implicated in the cellular uptake of adenosine and chemotherapeutic drugs,”Nat. Med. 1997, 3, 89-93.
Guo et al., “Targeted delivery of a peripheral benzodiazepine receptor ligand-gemcitabine conjugate to brain tumors in a xenograft model,”Cancer Chemother. Pharmacol. 2001, 48, 169-176.
Guo et al., “Selective Protection of 2′,2′-Diflurodeoxycytidine (Gemcitabine),”J. Org. Chem. 1999, 64, 8319-8322.
Howard et al., “Intracerebal drug delivery in rats with lesion-induced memory deficits,”J. Neurosurg. 1989 71(1):105-112.
Langer et al., , “Chemical and Physical Structure of Polymers as Carriers for Controlled Relaease of Bioactive Agents: A Review,”J Macromol. Sci. Rev. Macromol Chem. 1983, 23:61.
Langer, “New Method of Drug Delivery,” 1990,Science249:1527-1533.
Leibach et al., “Peptide transporters in the intestine and the kidney,”Ann. Rev. Nutr. 1996, 16, 99-119.
Levy et al., “Inhibition of Calcification of Bioprosthetic Heart Valves by Local Controlled-Release Diphosphonate,”Science1985 228: 190.
Mackey et al., “Functional nucleoside transporters are required for gemcitabine influx and manifestation of toxicity in cancer cell lines,”Anti-Cancer Drugs, 1998, 58, 4349-4357.
Mackey et al. “Gemcitabine Transport inXenopusOocytes Expressing Recombinant Plasma Membrane Mammalian Nucleoside Transporters,”J. Natl. Cancer Inst. 1999, 91, 1876-1881.
Maurel et al., Phase I trial of weekly gemcitabine at 3-h infusion in refractory, heavily pretreated advanced solid tumors.Anti-Cancer Drugs, 2001, 12, 713-717.
Miller et al., “Smoking cessation in hospitalized patients. Results of a randomized trial,”J. Med. Chem. 1997, 20, 409-413.
Nakashima et al. “Tetrazolium-based plaque assay for HIV-1 and HIV-2, and its use in the evaluation of antiviral compounds,”J. Virol Methods1989, 26, 319-329.
Patel et al., “Phase II Clinical Investigation of Gemcitabine in Advanced Soft Tissue Sarcomas and Window Evaluation of Dose Rate on Gemcitabine Triphosphate Accumulation,”J. Clin. Oncol. 2001, 19, 3483-3489.
Prasad et al., “Cloning and Functional Expression of a cDNA Encoding a Mammalian Sodium-dependent Vitamin Transporter Mediating the Uptake of Pantothenate, Biotin, and Lipoate,”J. Biol. Chem. 1998, 273, 7501-7506.
Prasad et al., “Molecular and functional characterization of the intestinal Na+-dependent multivitamin transporter,”Arch. Biochem. Biophys. 1999, 366, 95-106.
Richardson et al., “Synthesis and restriction enzyme analysis of oligodeoxyribonucleotides containing the anti-cancer drug 2′,2′-difluoro-2′-deoxycytidine,”Nucleic Acid Res. 1992, 20, 1763-1769.
Ritzel et al., “Molecular identification and characterization of novel human and mouse concentrative Na+-nucleoside cotransporter proteins (hCNT3 and mCNT3) broadly selective for purine and pyrimidine nucleosides (system cib),”J. Biol. Chem. 2001, 276, 2914-2927.
Ritzel et al., “Molecular cloning, functional expression and chromosomal localization of a cDNA encoding a human Na+
ucleoside cotransporter (hCNT2) selective for purine nucleosides and uridine,”Mol. Membr. Biol. 1998, 15, 203-211.
Ritzel et al., “Molecular cloning and functional expression of cDNAs encoding a human Na+-nucleoside cotransport
Cundy Kenneth C.
Gallop Mark A.
Peng Ge
Woiwode Thomas F.
Dorsey & Whitney LLP
Lewis Patrick T
XenoPort, Inc.
LandOfFree
Gemcitabine prodrugs, pharmaceutical compositions and uses... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Gemcitabine prodrugs, pharmaceutical compositions and uses..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Gemcitabine prodrugs, pharmaceutical compositions and uses... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4077634